darrinbaines.info — the framework that defines and validates how models are built and interpreted for the work of Darrin Baines Identity → darrinbaines.org
Health Economics · Validation · AI · Health Systems

Darrin Baines

Most models fail at the point of decision — where weak validation leads to rejection, delay, or loss of confidence.

Health systems are under structural financial pressure. HTA scrutiny is rising. AI is accelerating how evidence is generated — but not how it is validated.

The result: Models are being used to make decisions that they cannot fully withstand.

The shift is already happening

Pre-validation HTA is ending. The question is whether your models are ready.

Health economics is moving from model construction → to model validation

Validation is becoming the standard, not the exception.

Where organisations are exposed
  • ◆ HTA submissions under increasing scrutiny
  • ◆ Models that cannot be fully explained or defended
  • ◆ AI-generated evidence without governance
  • ◆ Growing data, but declining decision confidence
Available for engagements — responds within one working day
→ Request a Rapid Model Validation Review (2–3 weeks) → Pressure-Test Your HTA Model Before Submission
White Paper · Health Systems Analytics · 2026
Health Economics is Moving from Model Construction to Model Validation
The case for validated health economics in an era of AI-accelerated evidence
Most health economic models are never formally validated. They produce results, but the structure behind those results is rarely tested in a way that would withstand full scrutiny.
The Validation Gap
Dr Darrin Baines
Health Systems Analytics · 2026
PDF
↓ Download White Paper
Darrin Baines
Dr Darrin Baines
Founder, Health Systems Analytics
◆30+ years in health economics, policy, and HTA
◆50+ consultancy projects delivered
◆150+ published outputs
◆Former Professor of Health Economics
Coventry · Bournemouth · Lincoln
◆Former Interim Head of Health Economics
Clarivate
◆Former Director, Modelling & Meta-Analysis
OPEN Health
"
"His academic perspective on the underlying economics helped us think differently about the efficiency savings challenge faced by the NHS. We've already invited him back to see us again."
Claire Stoneham
Deputy Director, NHS Efficiency · Department of Health
Working with
Pharmaceutical
HTA submission under scrutiny?

I pressure-test your models before reviewers do — and build the validation infrastructure to defend them.

NHS Organisations
Under cost pressure?

I deliver defensible economic analysis and productivity frameworks that hold up in front of commissioners and decision-makers.

Ministries & Health Systems
Building HTA capacity?

I bridge UK HTA maturity with emerging health systems — bringing methodology, governance, and institutional knowledge.

AI Teams
AI generating evidence without governance?

I introduce AI with the validation infrastructure and governance framework that makes it credible to HTA bodies and regulators.

30+
Years delivering
50+
Projects completed
152
Published outputs
Why it matters

The question is no longer whether health economic models should be validated — it is whether your organisation will be ready when that becomes the standard.

Work with me
→ Pressure-test your models
→ Prepare for validation-first HTA
→ Introduce AI with governance
→ Strengthen decision confidence
→ Request a rapid model validation review (2–3 weeks) → Pressure-test your HTA model before submission
Organisations worked with
About

I help organisations move from model outputs → decision-ready evidence

The question organisations face is no longer whether health economic models should be validated — it is whether yours will be ready when that becomes the standard. Most models produce results. Very few are structurally validated. When scrutiny arrives, there is no time to rebuild.

I have spent 30 years working at the technical and policy frontline of health economics — close enough to see where models fail under pressure, and experienced enough to know what it takes to make them defensible. Pre-validation HTA is ending. The organisations that act before scrutiny arrives will define the next generation of practice.

I have delivered over 50 health economics projects for clients including the NHS, NIHR, pharmaceutical companies, charities, and the British Council. I combine methodological rigour with practical policy experience — producing work that is credible to academics, actionable for commissioners, and persuasive to decision-makers.

My consultancy, Health Systems Analytics, brings together health economics expertise with AI-assisted analysis and validation infrastructure — a combination uniquely positioned for the challenges facing NHS and life sciences organisations today.

How clients engage
◆ HTA submission pressure-testing
◆ AI integration with governance
◆ Strategic validation review
◆ Retained ongoing support
Pressure-test your HTA model before submission
"He is able to bring together a flow of new and innovative ideas with an ability to get things done and to make an impact. Also a great guy and fun to work with."
— Professor Mark Sculpher, Professor of Health Economics & Director, Centre for Health Economics, University of York
Royal Society Parliamentary Pairing Scheme Paired with Lord David Prior, Chairman of NHS England
Editorial boards Future Journal of Pharmaceutical Sciences; Journal of Pharmaceutical Policy and Practice
International networks UK–Egypt and UK–China health economics partnerships (British Council)
ISPOR speaker International health economics and outcomes research community
Canonical identity ORCID 0000-0001-9502-4678 · darrinbaines.org
Validation framework layer darrinbaines.info is the framework that defines and validates how models are built and interpreted — structured and made machine-readable.
Training Platform
healtheconomics.pro →
Learn it, do it, master health economics™

Practical, scenario-based health economics training combining Scenario-Based and Problem-Based Learning — bridging theory and real-world application for professionals who need results, not just theory.

◆ Practical problem-based courses — online & hybrid
◆ Taught by Dr Darrin Baines — 30 years of health economics expertise
◆ Free trial available — introduction to health economics course
Explore Courses Free Trial
Services

Where organisations come to me

"Our HTA submission isn't holding up under scrutiny."
"AI is changing evidence generation — we don't know how to govern it."
"We're under cost pressure and need defensible economic analysis."

These are not isolated problems.

They are symptoms of the same shift: health economics is moving from outputs → to validated evidence systems.

I target interventions where risk is highest. Every service is grounded in demonstrated research output and real consultancy delivery — not theoretical capability. I work with NHS organisations, pharmaceutical companies, government bodies, and international health systems.

VIVID New Platform

Validation & Analysis Layer for Health Economic Models

HTA evaluation is becoming more forensic. Reviewers now expect full traceability of assumptions, calculations, and outcomes. VIVID turns opaque models into fully traceable, validation-ready systems — parsing models, verifying assumptions, running analysis, and generating submission-ready outputs.

Enables submission-ready outputs across NICE, CADTH, HIQA without rebuilding models for each jurisdiction.

Validation
10 structural checks, verified to 1e-6 tolerance
Any Framework
One model → NICE · HIQA · CADTH · ZIN
PSA Ready
1,000-iteration PSA with CE plane, CEAC, CEAF
Audit Trail
Full input-to-output trace, NICE Table 1 format
Global HEOR Teams · Market Access · HTA Consultancies · NICE · CADTH · HIQA
Request VIVID briefing →

AI & Semantic Infrastructure for Health Economics

Few senior health economists combine deep HTA methodology with hands-on AI and semantic data capability. I bring both. AI-assisted HTA workflows, SHACL ontology design, linked data infrastructure, and knowledge graph architecture for interoperable, machine-readable evidence systems.

Health Systems · Life sciences · HTA bodies · Regulators
📊

Health Technology Assessment

Cost-effectiveness analysis, decision-analytic modelling (Markov, DES), NICE submission support, EQ-5D valuation, budget impact analysis, and AI-assisted evidence synthesis for HTA.

Pharma · MedTech · Biotech · HTA bodies
£

Drug Budget & Medicines Optimisation

Prescribing cost analysis, formulary economics, generic and biosimilar pricing strategy, PPRS advisory, and ICB medicines optimisation blueprint development.

Pharma · NHS ICBs · Commissioners · NICE
🏥

NHS Service Evaluation

Full economic evaluation of NHS innovations and service redesigns — from costing through modelling to commissioner-facing reporting. Experienced across clinical trials, observational studies, and service programmes.

NHS Trusts · ICBs · NIHR · Charities
💊

Pharmacy Practice & Reform Strategy

Strategic and economic advice on community pharmacy transformation — technology-enabled hubs, pharmacist prescribing, dispensing economics, NHS pharmacy integration, and future service models.

Community Pharmacy · Pharmacy Technology · Pharmacy Policy & Reform
⚖️

NHS Productivity & Resource Allocation

Productivity measurement frameworks, financial incentive design, resource allocation modelling, and efficiency analysis for NHS commissioners and policy teams.

NHS Productivity · Measuring Productivity Gains from AI · Health Systems Efficiency Monitoring & Improvement
📜

Prescribing History & Policy Advisory

Unique expertise in the historical development of UK prescribing policy — providing authoritative context for regulatory submissions, policy papers, and pharmaceutical strategy.

History · Policy · Institutional Analysis
🔍

Health Information & Authenticity

Frameworks for classifying and responding to health misinformation and disinformation. Evidence-based advisory on data authenticity, AI-generated evidence quality, and information integrity.

Validation & Verification · Semantic Layer · Knowledge Graphs · Misinformation & Disinformation
🎓

Health Economics Training

World-class tailored training programmes for health economics teams, NHS organisations, pharmaceutical companies, and universities. Delivered through Healtheconomics.pro — covering HTA methods, cost-effectiveness modelling, AI in health economics, and commissioning frameworks.

NHS Teams · Pharma · Universities · Health Ministries
🌍

International PharmacoEconomics

EQ-5D valuation, HTA capacity building, and pharmacoeconomics training with a particular focus on Saudi Arabia and the wider Middle East — supporting health systems as they develop and mature their HTA frameworks and evidence infrastructure.

Saudi Arabia · Middle East · Health Ministries · Universities
Research Depth

Built on 152 published outputs

Every consultancy claim is backed by peer-reviewed research. These eight clusters represent the depth of published work — self-curated and archived — that underpins each service offered.

38
published outputs
Pharmacy Practice Policy & Reforms
One of the most substantial bodies of work in UK pharmacy economics — covering technology-enabled hubs, pharmacist prescribing, and dispensing models.
39
published outputs
Controlling Drug Costs
The largest published body of work in the UK on drug cost control and prescribing economics — including the foundational ASTRO-PU metric still used by the NHS today.
28
published outputs
NHS & Health Systems Evaluations
A comprehensive evaluation record spanning RCTs, service innovations, and commissioning reform — from primary care to dementia care to NHS productivity.
17
published outputs
History of Prescribing & Dispensing
A unique scholarly asset — the most complete published history of UK prescribing policy from NHS origins to the present day. Rare intellectual territory.
11
published outputs
Health Technology Assessment & Economic Evaluation
A track record spanning cost-effectiveness modelling, EQ-5D valuation, NICE submissions, and AI-assisted evidence synthesis for regulatory decision-making.
9
published outputs
NHS Productivity & Resource Allocation
Efficiency measurement, allocation formulae, incentive design, and productivity frameworks — evidence that speaks directly to NHS finance teams and commissioners.
4
published outputs
Authenticity, Misinformation & Deception
Co-author of an internationally cited COVID-19 misinformation taxonomy — an increasingly relevant framework as AI-generated evidence floods health information systems.
6
key appointments
Qualifications & Professional Roles
PhD · Professor × 2 · Clarivate · Health Systems Analytics · Royal Society · Editorial boards.
Track Record

Selected project experience

Selected Consultancy Engagements
Pharmaceutical Company · Market Access
Developed NICE-submission economic model and budget impact analysis for a specialist medicine entering a crowded formulary. Delivered commissioner-facing briefing materials that supported market access negotiation.
NHS · Public Health Evaluation
Delivered health economics evaluation for the East Sussex Wellbeing and Employment Service (ESWE) — a PHIRST Light programme. Completed for Professor Mark Gussy, September 2024.
Clarivate · AI in HTA
As Interim Head of Health Economics, led build-out of AI and semantic data workflows for life sciences clients — including knowledge graph infrastructure applied to HTA evidence synthesis, reducing manual evidence processing time.
Department for Transport · Safety Economics
Delivering benefit-cost analysis for a Loughborough University DfT-commissioned study evaluating HGV blind-spot detection technologies (UNECE 151/159 and TfL PSS). Subcontracted expert economist for requirement R10. Ongoing.
Community Pharmacy · Public Health
Delivered health economics evaluation for the Lifeguard Pharmacy intervention — a first-response service in community pharmacy for people experiencing suicidal thoughts or domestic abuse. Co-developed with Professor Josie Solomon. Project completed.
British Council · Egypt Capacity Building
Led multi-year UK–Egypt pharmacoeconomics partnership delivering training, the national EQ-5D-5L valuation study, and a systematic review of Egyptian pharmacoeconomic literature — establishing a replicable capacity-building model.
"
"Darrin is a pleasure to work with and brings with him amazing knowledge and pragmatic insights and solutions to market access and health economics challenges. A strong and well-respected presenter."
Robert White
Global business leader & market access expert
"
"Darrin's a rare breed — a novel, creative thinker in health economics. It's always a bonus to have him on your methodology team."
Prof. Richard Fordham
Emeritus Professor of Public Health Economics
2022

EQ-5D-5L Valuation Study — Egypt

Led health utility valuation study establishing Egyptian population norms for the EQ-5D-5L instrument. Published in PharmacoEconomics.

International HTA
2023–24

AI & Machine Learning in HTA — Clarivate

As Interim Head of Health Economics, led application of AI and data science to health technology assessment workflows for life sciences clients.

AI · HTA
2018

Pharmacy Productivity Framework

Developed conceptual framework for measuring production and productivity in pharmacy practice. Published in Human Resources for Health.

Pharmacy · NHS
2020

COVID-19 Misinformation Taxonomy

Co-authored internationally cited framework defining misinformation, disinformation and malinformation during the COVID-19 infodemic.

Policy · Information
2014

ICCD Diabetes RCT — Economic Evaluation

Health economist on multicentre cluster randomised controlled trial evaluating intermediate care clinics for diabetes. Published in PLOS ONE.

RCT · NHS
2015

NHS Injury Costing — National Cohort Study

Economic analysis of NHS resource use and costs following unintentional injury across four NHS Trusts. Published in Journal of Public Health.

NHS Evaluation
2015–17

Namaste Care Dementia Programme

Economic modelling and costing analysis for NHS dementia innovation programme at Coventry University's Centre for Technology Enabled Health Research.

NHS · Dementia
2019

PharmacoEconomics Education in MENA — Web-Based Study

Led web-based research mapping the state of pharmacoeconomics education across the Middle East and North Africa region — identifying capacity gaps and informing the UK–Egypt knowledge exchange programme.

International · MENA · Education
International Work

Bridging UK HTA maturity with emerging health systems

The UK has spent 25 years building one of the world's most rigorous HTA systems — one that is now the global benchmark. Health ministries across MENA, Asia-Pacific, and beyond are now building their own, and they need advisors who understand both the methodology and the institutional context it took decades to develop. I bridge that gap.

I have led two major international health economics knowledge exchange networks — both supported by the British Council — and contributed to pharmacoeconomic capacity building across Egypt, China, and the Asia-Pacific region. As these systems mature and align with global evidence standards, the demand for experienced UK health economists who can translate method into policy has never been higher.

Available for international project work, HTA advisory, and capacity-building engagements.

International enquiries
EG

UK–Egypt Health Economics Partnership

British Council-supported pharmacoeconomics knowledge exchange with Cairo University and Future University Egypt. Delivered EQ-5D-5L national valuation study, pharmacoeconomics training, and systematic review of Egyptian pharmacoeconomic research.

CN

UK–China Health & Economy Partnership

Led health economics capacity building across multiple Chinese universities in collaboration with the Universities of Leeds, York and Sheffield. Contributed to development of HTA research capability in China's health system.

AP

Asia-Pacific Drug Policy Analysis

Comparative analysis of pharmaceutical policy reforms and drug price regulation across Australia, China, India, Malaysia, New Zealand, and South Korea.

IS

ISPOR International Speaker

Regular contributor to the International Society for Pharmacoeconomics and Outcomes Research — the global professional home of health economists and HTA specialists.

Testimonials

What colleagues say

"
He is able to bring together a flow of new and innovative ideas with an ability to get things done and to make an impact. Also a great guy and fun to work with.
MS
Professor Mark Sculpher
Professor of Health Economics & Director, Centre for Health Economics, University of York
"Darrin is a pleasure to work with and brings with him amazing knowledge and pragmatic insights and solutions to market access and health economics challenges. A strong and well-respected presenter."
Robert White
Global business leader & market access expert
"Darrin's a rare breed — a novel, creative thinker in health economics. It's always a bonus to have him on your methodology team."
Prof. Richard Fordham
Emeritus Professor of Public Health Economics
"I witnessed his outstanding capabilities interacting and engaging with stakeholders, applying the theory in daily business practice. His academic capability is just outstanding when coupled with his accumulated business acumen."
Alaa Darwish
Regional Commercial Leader, Middle East & Saudi Arabia, Pharma & Life Sciences
"As an economist, Darrin has a highly sophisticated understanding of, and approach to, data. He also has unusual imaginative and entrepreneurial flair — a brilliant collaborator."
Vicky Sargent
Director, CLGdotTV · NHS-funded digital projects
"Darrin was the epitome of professionalism and good humour when presenting, coaxing, or otherwise contributing — even when audiences were wilfully blind to his message."
Neil Ratcliffe
Experienced General Manager, commissioning consultancy
"Darrin provided some excellent interactive training sessions for pharmacists to help them understand the NHS market."
Professor Angela Alexander
Professor Emerita
Contact

Let's discuss your project

Most engagements begin with a 30-minute conversation. Tell me about your challenge and I will respond within one working day.

I work with NHS organisations, pharmaceutical companies, government bodies, charities, research councils, and international health systems — on independent advisory, project-based modelling, strategic reviews, and retained support.

✉
🔗
🌐
💼
Book a 30-minute validation assessment
Biographical Record
ORCID 0000-0001-9502-4678

Darrin Baines has spent three decades identifying what the health economics field has not yet fully named: that the models underpinning its most consequential decisions were never formally validated. His work — spanning NHS policy, pharmaceutical evidence, academic methodology, and AI infrastructure — has been oriented, consistently, toward closing that gap.

Baines has led health economics teams at OPEN Health and Clarivate and has delivered economic evaluations across more than twenty NHS service improvement programmes. He has held professorial appointments in health economics at Coventry University, Bournemouth University, and the University of Lincoln (visiting).

He designed and launched master's programmes in health economics at the Universities of Birmingham, South Wales and Cairo. He served as Regional Economist for NHS North West (2009–2012), supporting commissioning decisions across one of England's largest health systems.

His research spans health economics, health system design, pharmacy practice, and evaluation methodology. He has also published widely cited work on misinformation, disinformation, and malinformation.

Baines has led international knowledge-transfer networks in health economics linking UK universities with institutions in China and Egypt, funded by the British Council and GlaxoSmithKline.

Through Health Systems Analytics, he is developing a structured, machine-readable validation framework for health economic models — providing the governance and traceability infrastructure that HTA scrutiny increasingly demands. He continues international advisory work through Health Systems Analytics Ltd.

Canonical identity: darrinbaines.org · Validation framework: darrinbaines.info

Currently: developing a structured, machine-readable validation framework for health economic models through Health Systems Analytics. Available for advisory, project, and training engagements.
Book a 30-minute validation assessment →